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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine whether or not ceftobiprole is a
safe and effective treatment for complicated skin and skin structure infections
STUDY DESIGN: Review of all English language primary randomized controlled trials from 19962010
DATA SOURCES: Three randomized controlled trials were found using Pubmed and Cochrane
databases
OUTCOMES MEASURES: Skin or skin-structure infection cure with ceftobiprole intervention and
adverse effects of this new pharmaceutical. Cure or failure to cure skin infection was determined based
on both clinical and microbiological assessment. Adverse events were measured based on patient
reports, clinician reports, labs, and vital sign assessment.
RESULTS: Noel, Strauss et al. found statistically significant cure rates of complicated skin and skinstructure infections with intervention of ceftobiprole compared to the standard control arm. Noel, Bush
et al. found similar results when comparing ceftobiprole with the control arm. Both studies concluded
that ceftobiprole was non-inferior to the leading treatment for complicated skin infections, and caused
complete microbiological and clinical resolution of complicated skin infections. Schmitt-Hoffmann et
al. concluded that ceftobiprole was safe for human consumption with no severe adverse effects noted.
CONCLUSIONS: Cefrobiprole is comparable to vancomycin in both safety and effectiveness for
treatment for skin and skin-structure infections
KEY WORDS: Ceftobiprole, Skin infections; Skin structure infections, BAL5788
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INTRODUCTION
An uncomplicated skin infection is the colonization of epidermal and dermal tissue with a
parasitic pathogen. Complicated skin infections, as defined by Noel, Strauss et al, involve the
subcutaneous tissue or require significant surgical intervention and one or more of the following: a
wound infection, an abscess, or cellulitis.1 The most common pathogens causing skin and skin-structure
infections include Streptococcus pyogens, Staphylococcus aureus, and recently, an increase of
methicillin-resistant Staphylococcus aureus (MRSA). Treatment of complicated skin and skin-structure
infections typically begins with empiric broad-spectrum antibiotics such as vancomycin, which is then
tailored to a more narrow spectrum antibiotic based on sensitivity results. This review evaluates three
randomized controlled trials that compare ceftobiprole, a novel antibiotic, to standard treatment with
vancomycin for the treatment of complicated skin and skin-structure infections.
Ceftobiprole is an investigational novel pyrrolidinone cephalosporin still in clinical trials and
unavailable in the Unites States.1 It is a broad-spectrum anti-MRSA antibiotic developed in 2004 by
Basilea Pharmaceuticals and further developed and researched by Johnson and Johnson
Pharmaceuticals. It shows activity against multiple pathogens including methicillin-resistant
Staphylococcus aureus (MRSA), Enterobacteriaceae and Pseudomonas aeruginosa. The research
articles used in this review studied the safety and efficacy of this novel antibiotic on complicated skin
infections.
The diagnosis and treatment of complicated skin infections is within a physician assistant's
scope of practice. Physician assistants are involved in care in multiple specialties that regularly treat
patients with skin infections. Some of these include Dermatology, Family Medicine, Emergency
Medicine, Pediatrics, Internal Medicine and Surgery. Because complicated skin infections occur
commonly, physician assistants must stay abreast of changes and advancements in treatment options.
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The incidence of complicated MRSA related skin infections is showing an upward trend. MRSA
is now responsible for 60% of purulent skin and soft tissue infections in patients presenting to
emergency rooms in the United States.4 MRSA infections alone cost the healthcare system an estimated
$830 million- $9.7 billion in 2005 alone and were responsible for 278,203 hospitalizations in 2005. 4,5
In the coming years, physician assistants are expected to encounter multiple skin infections with
MRSA as a main causative pathogen. According to Graham et al's population based survey, 95 million
Americans carry S. aureus in their noses.5 Of these, 2.5 million (2.6% of carriers) carry MRSA.5 The
incidence of complicated MRSA infections is also increasing over time. Between 1999 and 2005, the
estimated number of S. aureus related hospitalizations increased 62%, from 294,570 to 477,927.5 The
number of serious complicated skin infections requiring hospitalizations is also increasing. Between
1999 to 2005, the estimated number of MRSA-related hospitalizations more than doubled, from
127,036 to 278,203.5 For these reasons, physician assistants must be aware of all potential ways to treat
complicated skin infections caused by an increasingly common MRSA pathogen.
Because MRSA has become an increasingly ubiquitous, physician assistants must consider the
possibility of MRSA as a causative agent in all skin infections and treat accordingly with a broad
spectrum antibiotic until further culture and sensitivity is available. Currently, the most commonly
used medication to treat these infections is vancomycin. However, new evidence from Noel et al
suggests that ceftobiprole may be an effective alternative to vancomycin in treating complicated skin
infections.
Ceftobiprole was developed in an effort to create more new agents with reliable activity against
MRSA. The trials selected by the author compare ceftobiprole to vancomycin, the current standard of
care for the treatment of skin infections due to gram positive bacteria in which methicillin resistance is
a significant concern.1
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not ceftobiprole is a safe
and effective treatment for complicated skin and skin-structure infections.

METHODS
Selected articles included adults 18 years of age and older with complicated skin and skinstructure infections. Interventions used varied by the study. Two studies examined the efficacy of
ceftobiprole by comparing ceftobiprole with vancomycin or vancomycin plus ceftazidime and one
study examined the safety of ceftobiprole. In the Noel, Bush et al. study, the intervention involved
combining ceftobiprole plus placebo vs. vancomycin plus ceftazidine.2 Noel, Stauss et al. intervene by
giving vancomycin vs ceftobiprole.1 Outcomes measured included cure of skin infection defined as
“resolution of all signs and symptoms of the infection or improvement to such an extent that no further
antimicrobial therapy was necessary,” and presence of significant adverse events.1 In Schmitt-Hoffman
et al (2004), safety was assessed by giving participants either placebo BID, 500 mg ceftobiprole BID or
750 mg ceftobiprole BID.3 The main focus of this study was to determine safety of the drug by
assessing adverse events including serious adverse events.
Three randomized controlled studies were used for this systematic review. The author
performed searches on Pubmed and Cochrane databases, using key words “ceftobiprole” and
“BAL5788,” and by limiting results to those written in English. Inclusion criteria consisted of articles
published in peer-reviewed journals and were chosen based on outcomes significant to the patient.
Articles were excluded if performed before 1996 or if participants were under age of 18. Both Noel et
al. studies used confidence intervals (CI) to determine significance. The Schmitt-Hoffmann et al study,
which examined the safety of ceftobiprole used number needed to harm (NNH) to assess adverse
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effects of the drug at different doses versus a placebo. Table 1 demonstrates the demographics used in
the studies examined.
Table 1: Demographics of included studies
Study
Type # pts Age
Inclusion
(yrs)
Criteria
Noel GJ,
Bush K et
al (2008)
1

RCT*

Noel GJ,
Strauss RS. RCT
et al
(2008)
2

SchmittHoffman
(2004)
3

RCT

784

Exclusion
Criteria

W/D

Interventions

Adults 18 years
Pts with allergic
Ceftobiprole 500
18-91 or older who
reactions to
118 mg BID x 7-14 days
have a clinical
cephalosporins or
or Vancomycin 1g
diagnosis of
vancomyocin,
BID x 7-14 days
complicated pregnant or lactating
skin and skin
women,
structure
neutropenia, HIV
infections
infected with low
caused by
CD4 count, diabetic
documented or
foot infections,
suspected
osteomyelitis,
Gram-positive
animal or human
bacteria
bites, recent
antimicrobial
treatment x >24
hours in last 7 days

828

19-92

16

19-38

RCT = Randomized Controlled Trial

Adults 18 yrs or
older
diagnosed with
skin or skin
structure
infection

Pts with foreign
body infection,
osteomyelitis,
critical limb
ischemia, septic
arthritis

>18 yrs
Completed
medical exam
within normal
limits

Completed medical
exam outside of
normal limits

66

0

Ceftobiprole 500
mg infusion over
120 min q 8 hrs x 714 days + Placebo
infusion over 60
min q 12 hrs x 7-14
days or Vancomycin
1 g infusion over 60
min q 12 hrs x 7-14
days + Cetazidine 1
g infusion over 120
min q 8 hrs x 7-14
days
Placebo BID x 8
days or
Ceftobiprole 500
mg BID x 8 days or
Ceftobiprole 750
mg BID x 8 days
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OUTCOMES MEASURED
Outcomes measured in this review include efficacy of ceftobiprole and safety of ceftobiprole.
Efficacy, in both Noel et al studies, was measured by categorizing outcomes dichotomously into either
skin infection cure or failure.1,2 Cure was defined as a complete resolution of all symptoms of the skin
and skin-structure infection or improvement to such an extent that no further antimicrobial therapy was
necessary.1 Failure was defined as a need for further treatment with a non-study drug or discontinuation
of the study drug after three days secondary to ineffectiveness.1,2
Efficacy outcomes were measured in a standardized way through both microbiological
assessment and clinical assessment. Microbiological assessment was measured via gram stain and
culture of the skin and skin-structure infection site.1,2 The offending pathogen was identified in this
way. At the end of treatment, a repeat gram stain and culture of infected are were taken. Negative gram
stain and culture indicated cure of skin infection. Clinical outcomes were measured based on blinded
clinician's assessment of the presence of signs and symptoms of skin infection.
Safety outcomes of ceftobiprole were measured by both Noel et al. studies and additionally by
Schmitt-Hoffmann et al. Safety data was collected by Schmitt-Hoffmann et al. via blood samples for
laboratory safety tests, vital signs and pt reported adverse events. An adverse event (AE) was defined as
any adverse change that occurred after a patient was given a study drug. The Noel et al. studies mainly
used patient reports for adverse reactions.

RESULTS
All results in the three analyzed studies utilized dichotomous data: skin infection cured or not
cured, and adverse effect or no adverse effect. Inclusion criteria for all studies included patients 18
years of age or older. Both Noel et al. studies included only those who were diagnosed with a
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complicated skin or skin structure infection. Cellulitis cases were limited to 20% of the final patient
population.1,2 Exclusion criteria included allergy or intolerability to cephalosporins or vancomycin,
severe renal dysfunction, hepatic dysfunction, pregnant or lactating women, neutropenia, HIV with low
CD4 counts, diabetic foot infections, animal or human bites, osteomyelitis, critical limb ischemia,
septic arthritis, or systemic antibiotics for more than 24 hours in the last 7 days.1,2
Noel, Bush et al. reported a cure rate of 90.5% for the Ceftobiprole group and 90.2% for the
group treated with vancomycin and ceftazidime which were proven to not be significantly different
(95% CI, -4.4%, 3.9%).2 The relative risk reduction (RRR) was 0.003 and the absolute risk reduction
(ARR) was 0.3%. This study determined the number needed to treat (NNT) was 333 participants
(Table 2).2
Noel, Strauss et al determined a cure rate of 93.3% of participants being treated with
ceftobiprole and 93.5% cure rate for those taking vancomycin which were not significantly different
(95% CI, -4.2%, -4.9%).1 The relative risk reduction was 0.002 and the absolute risk reduction was
found to be -0.2%. The number needed to treat for this study was -500 participants (Table 2).1

Table 2. Efficacy of Ceftobiprole vs Vancomycin on skin infections
Vancomycin 95% CI* of
Ceftobiprole Vancomycin
+
difference in
ceftazidime
cure rates
Noel, Bush, et
al (2008)

439/485
(90.5%)

N/A

220/244
(90.2%)

Noel, Strauss,
et al (2008)

262/282
(93.3%)

259/277
(93.5%)

N/A

RBI*

ABI* NNT*

-4.4% - 3.9% 0.30% 0.30%

333

-4.2% - 4.9% -0.20% -0.20% -500

*CI = Confidence Interval, RBI = Relative Benefit Increase, ARR = Absolute Benefit Increase, NNT =
Number Needed to Treat

Ceftobiprole was found to be effective against a number of common gram-positive bacteria
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according to both Noel et al. studies. Two organisms cultured and followed in both studies was
methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus
(MSSA).1,2 A summary of cure rates based on organism type can be found in Table 3. According to
both studies, ceftobiprole was found to be non-inferior to vancomycin in treating both MSSA and
MRSA infections.1,2 Noel, Strauss et al. found ceftobiprole cured 91.8% of MRSA infections and
vancomycin cured 90.0% of cases which was not significantly different (95% CI, -8.4%, 12.1%).1
Noel, Bush et al also found no significant difference between ceftobiprole and vancomycin when
treating MRSA.2 This study reported 89.7% MRSA cure rate for ceftobiprole and 86.1% cure rate of
MRSA in the vancomycin group which is not significantly different (95% CI, -8.0%, 19.7% ) (Table
3).2

Table 3. Cure rates for Staph. aureus infections

MRSA

MSSA

Study

Ceftobiprole
group

Control group
(Vancomycin)

95% CI

Noel, Strauss et
al. (2008)

56/61
(91.8%)

54/60
(90.0%)

-8.4, 12.1

Noel, Bush et
al. (2008)

78/87
(89.7%)

31/36
(86.1%)

-8.0, 19.7

Noel, Strauss et
al. (2008)

121/126
(96.0%)

108/112
(96.4%)

-5.2, 4.4

Noel, Bush et
al. (2008)

150/160
(93.8%)

84/90
(93.3%)

-5.8, 8.2

MRSA = Methicillin-resistant Staphylococcus aureus
MSSA = Methicillin-sensitive Staphylococcus aureus

Adverse events were also studied in the three randomized control trials. Noel, Strauss et al.
reported 52% rate of adverse events in the ceftobiprole group and 51% rate of adverse events in the
Vancomycin group.1 The relative risk increase (RRI) was 0.02 and the absolute risk increase (ARI) was
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0.01.1 The number needed to harm in this study was 100 participants (Table 4).1
The Noel, Bush et al. study reported an adverse event rate of 56% in the ceftobiprole group and
a 57% rate of adverse event rate for the vancomycin plus ceftazidime group.2 The relative risk increase
(RRI) was -0.02 and the absolute risk increase (ARI) was -0.01.2 The number needed to harm (NNH) in
this group was also 100 participants (Table 4).2
The final study, Schmitt-Hoffmann et al., reported a rate of 83% adverse events in the
ceftobiprole group and 50% adverse event rate in the placebo group. The reported relative risk increase
(RRI) was 0.66 and the absolute risk increase was 0.33.3 The number needed to harm in this study was
3 participants (Table 4).3

Table 4. Incidences of at least one adverse event in Ceftobiprole and Control groups
Ceftobiprole

Control group

RRI*

ARI*

NNH*

Noel, Strauss et
al. (2008)

203/389
(52%)

193/382
(51%)

2%

1%

100

Noel, Bush et al.
(2008)

304/543
(56%)

159/279
(57%)

-2%

-1%

-100

SchmittHoffmann et al.

5/6
(83%)

2/4**
(50%)

66%

33%

3

*RRI = Relative Risk Increase, ARI = Absolute Risk Increase, NNH = Number Needed to
Harm
**Schmitt-Hotffmann compared Ceftobiprole to placebo

The incidence of serious events were also recorded in all three analyzed studies. Serious adverse
events were defined as any experience that was life threatening, required hospitalization, or resulted in
death.1,2 In Noel, Strauss et al. 6% of participants in the ceftobiprole group and 6% of participants in
the vancomycin group also reported serious adverse events.1 In Noel, Bush et al. 7% experienced
serious adverse events while taking ceftobiprole and 9% while taking vancomycin.2 The Schmitt-
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Hoffmann et al. study reported no serious adverse events (Table 5).3
Table 5. Incidence of serious adverse events (AE)
Ceftobiprole

Vancomycin

Noel, Strauss et al.
(2008)

24/398
(6%)

23/382
(6%)

Noel, Bush et al. (2008)

39/543
(7%)

24/279
(9%)

Schmitt-Hoffmann et
al.

0/16
(0%)

N/A

Losses to follow up were recorded and all individuals leaving the study were accounted for. In
Noel, Strauss et al. 15% of the participants were lost to follow up.1 The most common reasons for loss
to follow up included adverse events or concomitant illness (35 patients), non-cooperation (28
patients), and administrative issues (21 patients).1 In Noel, Bush et al. 8% discontinued, with most
common reason cited as loss to follow up accounting for 3%.2 There were no patients lost to follow up
in Schmitt-Hoffmann et al.3

DISCUSSION
One limitation of the Schmitt-Hoffmann et al. safety trial was the duration of treatment.
Ceftobiprole was administered for 8 days in this study and adverse effects only measured during that
time. The Noel et al. studies used ceftobiprole for an average of 9.0 days and a range of 7-14 days.1,2
More adverse events may have occurred if the drug was administered for a longer duration. In order to
adequately assess safety of a drug it should be tested at the maximum amount of time potentially used
by clinicians. This way delayed adverse events can be more accurately measured and thus safety of the
drug can be determined.
Another limitation is the clinical cure of infection. This is, by nature, subjective and could have
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wide variation based on clinician assessment. The standard used for clinical cure was defined as
“resolution of all signs and symptoms of infection,” which may have a wide range of meaning and
provider to provider dissonance. There is no way to fully eliminate provider subjectivity and this is a
perceived weakness in the study.
Another limitation of this review is the fact that both of the main studies determining efficacy
were performed by the same lab and headed by the same researcher, Gary Noel. There could be built in
bias in reporting results based on researchers desire to produce positive efficacy results. In addition,
both of the main studies were funded by Johnson & Johnson Pharmaceuticals who have an invested
interest in finding an alternative to vancomycin which is currently mainly produced by a Hospira, a
competing Pharmacutical company. More studies need to be performed by other non-biased researchers
in order to determine true effectiveness.
At the time this article was written, ceftobiprole was available in Canada and Switzerland but
was under review by regulatory authorities and still unavailable in the United States. More research is
needed in order for ceftobiprole to be considered a safe and effective alternative to vancomycin and for
it to be marketable as such.
One disadvantage to using this medication is that it can only be given intravenously. This limits
its use to inpatient care only. In order for a patient to be discharged with a skin infection they need to be
managed with a medication by mouth which in this case would require a medication change. Further
research would need to be conducted to measure effectiveness of switching from ceftobiprole to a po
medication to be taken upon discharge

CONCLUSION
The evidence from these three clinical trials support the conclusion that ceftobiprole is as safe
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and effective as vancomycin, the standard treatment for curing complicated skin and skin structure
infections. The studies reviewed provide supporting evidence that intervention with ceftobiprole leads
to complete resolution of complicated skin and skin structure infections, both microbiologically and
clinically. The conclude that ceftobiprole may be considered a reasonable alternative to vancomycin or
combination treatments in the event the patient is allergic to vancomycin or the bacteria is vancomycin
resistant.
Ceftobiprole is proven effective against gram-positive pathogens, including Staphylococci
which is a leading cause of complicated skin and soft tissue infections. It has also been proven effective
against MRSA, which is a significant concern for health care providers treating complicated skin
infections.
The evidence also shows that ceftobiprole is a safe agent for consumption by patients. Although
multiple adverse effects were noted, minimal serious adverse effects were attributed to ceftobiprole in
the studies performed. The incidence of adverse effects was on par with or less than the rate of adverse
events for vancomycin.
Despite the limitations noted here, the reviewed studies present evidence that ceftobiprole is an
effective alternative to vancomycin in treating gram positive complicated skin and skin-structure
infections.
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